Recent news on Carvedilol

A simple reminder will do: Increasing the use of evidence-based ...  -  25 May 2007
TheHeart.Org,The reminder said, "Note: Patients with reduced left ventricular ejection fraction have a survival benefit with beta blockers (initial dose: carvedilol

GlaxoSmithKline officials describe recent developments.  -  May 17, 2007
Therapeutics Daily (subscription) (press release),Report 1: GlaxoSmithKline (NYSE: GSK) announced today that Coreg CR(tm) (carvedilol phosphate) extended-release capsules, a once-a-day beta-blocker,

'Big Pharma' invents illnesses  -  May 14, 2007
St. George Daily Spectrum,One such ad for Coreg-Carvedilol, a heart medicine, consisted of a six-page discourse, some 2500 words - in fine print - explaining the expectations,

International market boosts Dr Reddy's revenue  -  May 23, 2007
In-PharmaTechnologist.com,...drug (which already has Mylan and Pfizer generics) and Glaxo's Coreg (carvedilol) heart disease treatment when their patents expire later this year.

GSK hit by strong sterling but underlying growth is good  -  Apr 26, 2007
Pharma Times (subscription),Sales of Lamictal (lamotrigine) for epilepsy were up 17% to £250 million, while heart disease drug Coreg (carvedilol) increased 8% to £217 million.

THOMSON FINANCIAL NEWS TOP STORIES UK 1605 BST  -  Apr 25, 2007
FXstreet.com The Futures Market,...protection in three key products, but profits were boosted by a one-off settlement payment from Roche over carvedilol, a treatment for heart patients

Matrix reloaded  -  Apr 29, 2007
Business Standard,...thanks to over $15 million revenue estimated from the new product opportunities like citrazine, cipro-xr, carvedilol, venlafaxin and zolpidem etc.

Glaxo Q1 profit dips to $4.3bn on strong pound  -  26 Apr 2007
Gulf Times,...was boosted by other operating income of £207mn due to a settlement with Switzerland’s Roche over blood pressure drug carvedilol and higher royalties.

UPDATE 3-Glaxo Q1 profits down 1 pct, hit by strong pound  -  Apr 25, 2007
Reuters.uk,VX: Quote, Profile , Research) over blood pressure drug carvedilol and higher royalties. Sales, meanwhile, came in below forecasts of 5.75 billion and Glaxo

THOMSON FINANCIAL NEWS TOP STORIES UK 1605 BST  -  Apr 25, 2007
FXstreet.com The Futures Market,...protection in three key products, but profits were boosted by a one-off settlement payment from Roche over carvedilol, a treatment for heart patients

GlaxoSmithKline upgraded to "buy"  -  Apr 24, 2007
newratings.comIf GlaxoSmithKline receives the patent protection for carvedilol phosphate, the switch rate for the drug is expected to reach 65%, the analysts say.

GSK Pharma to launch new drug  -  Mar 31, 2007
Myiris.com,Glaxo SmithKline (GSK) is set to launch Carvedilol, a cardiovascular drug from Swiss drugmaker Roche, in the next two months, reports Business Line.

GlaxoSmithKline Acquires Exclusive Rights To Over-the-counter ...  -  25 Feb 2007
Medical News Today (press release),GSK and Roche have also agreed to settle all arbitration procedures between the two companies relating to the licensing and co-marketing of carvedilol.

Roche and GSK agree on two transactions  -  Feb 21, 2007
PipelineReview.com (press release),...both companies agreed to settle all arbitration procedures between the two companies relating to the licensing and co-marketing of carvedilol.

GlaxoSmithKline acquires exclusive rights to over-the-counter orlistat  -  Feb 20, 2007
WebWire (press release),GSK and Roche have also agreed to settle all arbitration procedures between the two companies relating to the licensing and co-marketing of carvedilol.

UPDATE 2-Roche out-licenses non-US Alli rights to Glaxo  -  Feb 20, 2007
ReutersRoche and Glaxo have also agreed to settle all arbitration procedures related to licensing and co-marketing blood pressure treatment carvedilol, Roche said.

GSK and Roche sign another orlistat OTC deal  -  Feb 20, 2007
Pharma Times (subscription),...agreed to settle all arbitration procedures between the two companies relating to the licensing and co-marketing of the beta blocker Coreg (carvedilol).

GlaxoSmithKline watches your weight  -  Feb 22, 2007
In-PharmaTechnologist.com,...between the two companies relating to the licensing and co-marketing of carvedilol used in the treatment of mild to moderate congestive heart failure.

Pipeline paying dividends as GSK posts strong earnings rise  -  Feb 9, 2007
Pharma Times (subscription),...by a new indication, to treat primary generalised tonic-clonic seizures, while heart disease drug Coreg (carvedilol) increased 39% to £199 million.

Central sleep apnea suppressed by carvedilol; obstructive sleep ...  -  18 Jan 2007
TheHeart.Org,When analyzed according to beta-blocker use (carvedilol in all cases), patients taking the drug had a lower apnea-hypopnea index (AHI) and central apnea

Genes Determine Heart Drug Effectiveness  -  18 Jan 2007
HeartZine,Response of the receptors to three different beta blockers – bisoprolol, metoprolol, and carvedilol was studied to understand this.

Increased agonist effect with carvedilol in beta-adrenergic ...  -  Jan 5, 2007
TheHeart.Org,..."It will be interesting to investigate whether patients carrying the ARG389 polymorphism may benefit from treatment with carvedilol as opposed to other beta

Blood pressure drugs useful for breathing problem  -  Jan 9, 2007
Scientific AmericanThe current findings are based on study of 45 patients with chronic heart failure, of whom 27 were taking the beta-blocker carvedilol and 18 who were not.

Genetic Mutation Alters Response To Heart Failure Drugs  -  Jan 5, 2007
Medical News Today (press release),In contrast, carvedilol treatment induced a response from the Arg389 variant that was 2.5-fold that of the Gly389 variant.

Researchers: Genes affect response to heart failure drugs  -  Jan 4, 2007
Asbury Park Press,They looked at how the receptors responded to three different beta blockers - bisoprolol, metoprolol, and carvedilol.

Sustained-release carvedilol approved for multiple indications  Oct 27, 2006
Philadelphia, PA - The US Food and Drug Administration has approved a once-daily form of the beta blocker carvedilol (Coreg CR) for the treatment of patients ... -TheHeart.Org, Heart Disease :: GlaxoSmithKline's COREG, carvedilol phosphate for ...  Oct 21, 2006
GlaxoSmithKline (NYSE: GSK) and Flamel Technologies (NASDAQ:FLML) announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended-release capsules ... -SpiritIndia, FDA Approves New, Once-a-Day Coreg CR(TM) (Carvedilol Phosphate) ...  Oct 23, 2006
Coreg CR will utilize Flamel's proprietary Micropump(R) technology, which controls the delivery of carvedilol helping to maintain appropriate amounts of ... -DG News Mechanical 'Artificial Hearts' Can Return Heart To Normal And ...  Nov 5, 2006
The drugs used were lisinopril, carvedilol, spironolactone and losartan in the first stage of treatment and bisoprolol and clenbuterol in the second. ... -Medical News Today (press release), From The Brink Of Death To A Normal Life - Can LVADs Plus Drug ...  Nov 1, 2006
...the first stage of the pharmacologic regimen consisting of four drugs intended to enhance reverse remodeling—lisinopril to 40 mg daily, carvedilol to 50 mg ... -Medscape (subscription) Mechanical Assist Plus Potent Medical Therapy Revives Failing ...  Nov 1, 2006
Patients were given a combination of combination of Zestril (lisinopril), Coreg (carvedilol), Aldactone (spironolactone) and Cozaar (losartan) to reverse ... -MedPage Today, Left Ventricular Assist Device and Drug Therapy for the Reversal ...  Nov 1, 2006
The patients underwent implantation of left ventricular assist devices and were treated with lisinopril, carvedilol, spironolactone, and losartan to enhance ... -New England Journal of Medicine (subscription), FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of ...  Oct 20, 2006
NYSE: GSK - News) and Flamel Technologies (Nasdaq: FLML - News) today announced FDA approval of once-a-day Coreg CR(TM) (carvedilol phosphate) extended-release ... -Yahoo! News (press release) FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of ...  Oct 20, 2006
20 /PRNewswire-FirstCall/ -- GlaxoSmithKline and Flamel Technologies today announced FDA approval of once-a-day Coreg CR(TM) (carvedilol phosphate) extended ... -International News Service, Flamel Technology Reveals FDA Approval For Once-Daily Heart Drug ...  Oct 23, 2006
...charts | news | PowerRating), a biopharmaceutical company, revealed US Food and Drug Administration approval for Coreg CR - carvedilol phosphate extended ... -Trading Markets, GlaxoSmithKline, Flamel Technologies Get FDA Nod For Coreg CR To ...  Oct 20, 2006
FLML | charts | news | PowerRating) on Friday revealed that the US Food and Drug Administration or FDA approved Coreg CR or carvedilol phosphate, a once-a-day ... -Trading Markets, Beta blockers beneficial in HF with preserved LVEF?  Oct 27, 2006
Overall, 227 patients had a beta blocker prescribed at discharge—including carvedilol (up to a dose of 50 mg/day), metoprolol (up to 200 mg), bisoprolol (up ... -TheHeart.Org, FDA Approves GlaxoSmithKline (GSK) and Flamel Technologies (FLML) ...  Oct 23, 2006
COREG CR will utilize Flamel's proprietary Micropump technology, which controls the delivery of carvedilol helping to maintain appropriate amounts of medicine ... -StreetInsider.com (subscription), Go-Ahead Given to Four Drugs for Cardio Conditions, Eczema, MS ...  Oct 23, 2006
GlaxoSmithKline's Coreg CR (carvedilol phosphate extended release capsules) has been authorized to treat hypertension, postmyocardial infarction left ... -Genetic Engineering News (press release), Antiarrhythmic Therapy for Prevention of Implantable Cardioverter ...  Sep 12, 2006
However, 3 different -blockers were used and, among them, carvedilol has greater antiarrhythmic potential than either metoprolol or bisoprolol. ... -Journal of American Medical Association (subscription)

Antiarrhythmic Therapy for Prevention of Implantable Cardioverter ...  Sep 12, 2006
There is some evidence of specific antiarrhythmic efficacy of carvedilol in experimental studies. 1-2 However, no properly designed ... -Journal of American Medical Association (subscription)

FDA safety labeling changes for carvedilol, amiodarone  -  Nov 17, 2006
TheHeart.Org,On August 28, 2006, the FDA approved safety labeling changes for carvedilol to warn of potential complications associated with its use in diabetic patients.

FDA Safety Changes: Coreg, Cordarone, Nafcillin  -  Nov 17, 2006
Medscape (subscription)On August 28, the FDA approved safety labeling changes for carvedilol (Coreg tablets, made by GlaxoSmithKline) to warn of potential complications associated

FDA Approves New, Once-a-Day COREG CR for the Treatment of Three ...  -  Nov 13, 2006
Pharmaceutical Processing,GSK and Flamel Technologies have announced FDA approval of once-a-day Coreg CR (carvedilol phosphate) extended-release capsules, for the treatment of three

Clinical Trials Update: Nov. 16, 2006  -  Nov 16, 2006
Forbes,This trial will evaluate the effectiveness and safety of treatment with carvedilol controlled release formulation (COREG CR), Lisinopril (Zestril),

Failed heart drug could be a 'genetically targeted' success  Jul 10, 2006
Another beta blocker, carvedilol, sold as Coreg, has become a mainstay of heart failure treatment. In a study of 2,289 patients, carvedilol ... -USA Today

Treating heart failure  Jul 8, 2006
These include carvedilol, bisoprolol, metoprolol succinate (the last one is a once daily drug which is not available in Malaysia; the available metoprolol ... -Malaysia Star

Dosages in Combination Therapy Not Related to Number of ...  Jun 22, 2006
...reference). Patients were also taking bisoprolol, carvedilol, metoprolol, captopril, enalapril, lisinopril, ramipril, and candesartan. ... -DG News

Heart Failure Patients With Renal Insufficiency Often ...  Jun 22, 2006
Renal insufficiency was also associated with a significantly lower dose of carvedilol (17.5 mg for those with renal insufficiency vs 26.6 mg for those with ... -DG News

Expert Opinion on Drug Discovery - Harmonising Drug Discovery in ...  Jun 21, 2006
The launch issue of this exciting publication is now available online at http://www.expertopin.com/edc, and includes a case history of carvedilol by Robert ... -Yahoo! News



In-licensing is in, but how long will it last?  16 May 2006
...on a deal with a Japanese company for a cardiac product, the company has tied up with Eisai for rabeprazole and with Swiss drug maker Roche for carvedilol. ... - Daily News & Analysis

Taro Pharma Granted Tentative ANDA Approvals For Carvedilol ...  Apr 24, 2006
...that it has received tentative approval from the US Food and Drug Administration for its Abbreviated New Drug Applications for Carvedilol Tablets, 3.125 mg ... - Trading Markets

Taro Pharma Receives Tentative Approval From FDA For Carvedilol ...  Apr 24, 2006
...charts | news | PowerRating) revealed that it has received tentative approval from the FDA for its Abbreviated New Drug Applications for Carvedilol Tablets and ... - Trading Markets

Taro Receives Tentative ANDA Approvals For Carvedilol Tablets and ...  Apr 24, 2006
...received tentative approval from the US Food and Drug Administration ("FDA") for its Abbreviated New Drug Applications ("ANDA") for Carvedilol Tablets, 3.125 mg ... - PharmaLive.com

AXE THREAT PLANT WINS 100 JOBS  May 12, 2006
Now Glaxo will recruit specialists from agencies over the next few months to help the plant's workers make rosiglitazone and carvedilol to cope with a sudden ... - Glasgow Daily Record

Biovail Reports First-Quarter 2006 Financial Results; Company ...  May 11, 2006
...ongoing progress of Biovail's product pipeline, which includes development efforts for a bupropion salt, a once-daily formulation of carvedilol, and separate ... - Genetic Engineering News

Not all guidelines on treating heart failure in adults apply to ...  May 2, 2006
However, preliminary analysis of the results of a multicenter study of carvedilol in 140 children with heart failure (presented at the 2006 American College of ... - AAP News (subscription)

FDA approves 3 Taro drugs  Apr 24, 2006
...has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDA) for carvedilol tablets, 3.125 mg ... - Globes

Booster dose  May 7, 2006
...for the regulated markets. Among the new products that will be produced by Wanbury are sertraline and carvedilol. The company has ... - Economic Times

Taro Pharmaceutical Gets Tentative ANDA OK For Two Drugs  Apr 24, 2006
...(TARO) said Monday it received tentative approval from the US Food and Drug Administration for its abbreviated new drug applications for carvedilol tablets and ... - Therapeutics Daily (subscription)

GSK sees better-than-expected 1Q  Apr 28, 2006
...including Seretide/Advair, its Avandia (rosiglitzone) diabetes franchise (up 24% to £384 million), and the cardiovascular agent Coreg (carvedilol; up 53% to ... - Pharma Times (subscription)



GSK plans to launch cardio drug after July  Mar 1, 2006
GlaxoSmithKline Pharmaceuticals (GSK India) would shortly roll out Carvedilol, the blockbuster cardiovascular drug licensed from the Swiss pharma major Roche ... - Business Standard,

Mylan gets nod for Coreg generic  Feb 24, 2006
Mylan's application is for four different strengths of Carvedilol tablets, the generic version of the Coreg Tablets, which had annual US sales of approximately ... - Pharmaceutical Business Review

Wrap up: Sensex adds 61 points  Mar 2, 2006
GlaxoSmithKline Pharmaceuticals inched up 0.07% (Rs1312.35), the company would bring Carvedilol, the blockbuster cardiovascular drug licensed from the Swiss ... - Myiris.com,

Mylan gets tentative FDA OK for Coreg  Feb 23, 2006
The approval covers 3.125 milligram, 6.25 milligram, 12.5 milligram and 25 milligram strength tablets of carvedilol, the active ingredient in Coreg. ... - BusinessWeek

Myocarditis During Clozapine Treatment  Feb 14, 2006
...treatment with ramipril (an angiotensin-converting enzyme inhibitor) at 2.5 mg/day, intravenous furosemide (a diuretic) at 20 mg bid, and carvedilol (a beta ... - Am J Psychiatry (subscription)

2005 - the year of recovery for GSK  Feb 9, 2006
...for epilepsy/bipolar disorder, climbed 24% to £849 million; Valtrex (valaciclovir), for herpes, was up 21% to £695 million; and Coreg (carvedilol) for heart ... - Pharma Times (subscription),

2005 - the year of recovery for GSK  09 Feb 2006
...for epilepsy/bipolar disorder, climbed 24% to £849 million; Valtrex (valaciclovir), for herpes, was up 21% to £695 million; and Coreg (carvedilol) for heart ... - Pharma Times (subscription)

Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA ...  Jan 31, 2006
...today that the US Food and Drug Administration (FDA) have granted tentative approval for the Company's ANDA for the remaining strengths of Carvedilol tablets. ... - PharmaLive.com

Biovail expects rush of late-stage trials in 2006  Jan 12, 2006
...late-stage trials are its once-daily treatment for chronic pain, Tramadol/NSAID QD combination, targeted for late 2006, and its Carvedilol QD hypertension ... - Reuters Canada

Generics Erosion will Result in Slow Growth of Market to Treat ...  Feb 1, 2006
...finds that recent guidelines recommending more widespread use of beta blockers should spur near- term increased sales of carvedilol, GlaxoSmithKline's Coreg ... - PR Newswire

Biovail expects flurry of late-stage trials in 2006  Jan 12, 2006
Among the products expected to enter the late-stage trial phase are its Tramadol/NSAID QD combination targeted for late 2006 and its Carvedilol QD targeted for ... - Metro Toronto

Amiodarone Plus Beta-Blocker Prevents ICD Shocks  Jan 11, 2006
...the occurrence of ICD shocks in 412 patients who were randomized to receive amiodarone plus a beta-blocker (either metoprolol, carvedilol, or bisoprolol ... - Medscape (subscription)

Prognosis better for biotechs  Jan 14, 2006
That includes its once-daily treatment for chronic pain, Tramadol/NSAID QD combination, targeted for late 2006, and its Carvedilol QD hypertension treatment ... - Metro Toronto

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional